<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223012</url>
  </required_header>
  <id_info>
    <org_study_id>P16-321</org_study_id>
    <nct_id>NCT03223012</nct_id>
  </id_info>
  <brief_title>Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis, in the Portuguese National Health Service</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient
      reported outcomes and utilization of health resources over 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Medication Possession Ratio (MPR)&gt;=80%</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The variable MPR will be used, considering in the numerator the sum of days supply between start of observation (baseline) and last prescription dispensed (including the days of last prescription) and as denominator the number of days elapsed between baseline and last prescription dispensed (including the days of last prescription).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections administered/ prescribed for adalimumab</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed based on patient diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Patient's overall satisfaction with AbbVie Care 2.0 program</measure>
    <time_frame>At 12 months</time_frame>
    <description>Patient's overall satisfaction with AbbVie Care 2.0 program is scored at 1: Very good, 2: Good and 3: Less satisfying.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Sick Leaves</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing work time lost due to other reasons than health problems during previous last seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent by the Patient to Refill Prescription</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the work productivity indicator over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Inpatient Days</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Visits</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Working Status</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by the proportion of patients employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MPR&gt;=80%</measure>
    <time_frame>At Month 6</time_frame>
    <description>The variable MPR will be used, considering in the numerator the sum of days supply between start of observation (baseline) and last prescription dispensed (including the days of last prescription) and as denominator the number of days elapsed between baseline and last prescription dispensed (including the days of last prescription).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Treatment Satisfaction Questionnaire for Medication (TSQM)-II</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>This 14-point measure attempts to show that adherence is expected to be related with patients' satisfaction with therapy and such satisfaction can be a function of not only the effect of the treatment, but also the services offered. Domains include: Effectiveness, Side effects, Convenience and Global satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in EuroQoL (EQ-5D) score</measure>
    <time_frame>From Month 0 to Month 12</time_frame>
    <description>EQ-5D considers five attributes of quality of life evaluation, i.e., mobility, self-care, usual activity, pain/ discomfort, and anxiety/ depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complementary Exams/ Techniques</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent by the Health Care Providers (HCPs) During Medical Appointments</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Patient Activation Measure (PAM-13)</measure>
    <time_frame>From Month 0 to Month 12</time_frame>
    <description>This is a powerful and reliable measure of patient activation. It is 13-item measure used to assess the patient knowledge, skill, and confidence for self-management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Beliefs about Medication Questionnaire (BMQ)</measure>
    <time_frame>From Month 0 to Month 12</time_frame>
    <description>The BMQ comprises two sections: the BMQ-Specific, which assesses representations of medication prescribed for personal use and the BMQ-General, which assesses beliefs about medicines in general. This questionnaire is validated for use in Portugal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment- General Health (WPAI-GH)</measure>
    <time_frame>From Month 0 to Month 12</time_frame>
    <description>WPA-GH assesses the impact of general health problem on work productivity and daily activities during the previous 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Outpatient Visits (in-office and remote) in Hospital Setting</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing the use of health resources over 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Sick Leaves</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is assessed by reviewing work time lost due to health problems during previous seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are still on adalimumab after 6 and 12 months</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is used to assess persistence and it could be done using pharmacy refills.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Psoriasis and Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Participants not included in the AbbVie care program</arm_group_label>
    <description>Participants receiving adalimumab not included in the AbbVie care patient support program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants included in the AbbVie care</arm_group_label>
    <description>Participants receiving adalimumab included in the AbbVie care patient support program.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants receiving adalimumab in routine clinical practice in Portugal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis
             (RA), psoriatic arthritis (PsA), axial spondyloarthritis (SpA) or psoriasis (Pso)
             according to the treating physician

          -  Adalimumab was started within 1 month prior to study enrollment

          -  Adalimumab was introduced based on current clinical practice criteria (i.e., the
             prescription of adalimumab was clearly separated from the decision to include the
             participants in this study)

          -  No prior record of adalimumab treatment

          -  Adalimumab was administered according to product label

          -  Naïve or previously experienced with biologic treatment

          -  Participant is able and willing to provide written authorization to disclose and use
             personal health information (informed consent), and to agree that data will be
             collected and provided to AbbVie

        AbbVie Care 2.0 Cohort-specific inclusion criteria:

          -  Initiated the AbbVie care program within the first month after starting adalimumab.

        Exclusion Criteria:

          -  Definitive discontinuation of adalimumab before being proposed to participate in the
             study

          -  Participated in any clinical experimental research within the 2 months prior to
             enrollment

          -  Pregnant or breastfeeding female participants

          -  Participant not able or not willing to comply with the requirements of this study
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Pais de Ramos</last_name>
    <phone>351 211908410</phone>
    <email>miguelramos@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital do Espirito Santo de Evora</name>
      <address>
        <city>Évora</city>
        <zip>7000</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adalimumab</keyword>
  <keyword>Humira®</keyword>
  <keyword>AbbVie patient care support program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

